Pharmacogenomic (PGx) testing is gaining recognition from physicians, pharmacists and patients as a tool for evidence-based medication management. However, seemingly similar PGx testing panels (and PGx-based decision support tools) can diverge in their technological specifications, as well as the genetic factors that determine test specificity and sensitivity, and hence offer different values for users. Reluctance to embrace PGx testing is often the result of unfamiliarity with PGx technology, a lack of knowledge about the availability of curated guidelines/evidence for drug dosing recommendations, and an absence of wide-spread institutional implementation efforts and educational support. Demystifying an often confusing and variable PGx marketplace can lead to greater acceptance of PGx as a standard-of-care practice that improves drug outcomes and provides a lifetime value for patients. Here, we highlight the key underlying factors of a PGx test that should be considered, and discuss the current progress of PGx implementation.

药物基因组学（PGx）测试作为基于证据的药物管理工具已获得医师，药剂师和患者的认可。但是，看似相似的PGx测试小组（和基于PGx的决策支持工具）在技术规格以及决定测试特异性和敏感性的遗传因素上可能会有所不同，因此为用户提供了不同的价值。不愿接受PGx测试的原因通常是由于对PGx技术不熟悉，缺乏关于所制定的指导原则/药物剂量推荐证据的知识，以及缺乏广泛的机构实施工作和教育支持。揭开一个经常令人困惑和变化不定的PGx市场的神秘面纱，可以使PGx作为一种护理标准实践得到更大的接受，这可以改善药物的疗效并为患者提供终生价值。在这里，我们重点介绍了应该考虑的PGx测试的关键基础因素，并讨论了PGx实施的最新进展。